Back to top
more

Exelixis (EXEL)

(Real Time Quote from BATS)

$37.33 USD

37.33
1,710,870

+0.52 (1.41%)

Updated Aug 5, 2025 01:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter.

Zacks Equity Research

Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 75.00% and 11.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Exelixis (EXEL) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Exelixis Starts Study on Cabometyx Combo in Kidney Cancer

by Zacks Equity Research

Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.

Zacks Equity Research

Exelixis (EXEL) in Focus: Stock Moves 7.6% Higher

by Zacks Equity Research

Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the first quarter on strong performance of Revlimid and Eliquis.

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Exelixis (EXEL) Q1 Earnings Expected to Decline

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

EXEL or RGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Zacks Equity Research

Company News for Apr 21, 2020

by Zacks Equity Research

Companies In The News Are: CYCC, CODX, NBY, EXEL

Zacks Equity Research

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4

by Zacks Equity Research

Exelixis' (EXEL) Q4 results are a mixed bag, as earnings beat, while sales marginally miss estimates.

Zacks Equity Research

Exelixis (EXEL) Tops Q4 Earnings Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 46.67% and -0.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.

Zacks Equity Research

Exelixis (EXEL) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Exelixis (EXEL) closed at $17.60, marking a +0.69% move from the previous day.

Zacks Equity Research

Roche Submits Application for Tecentriq-Avastin Combo in HCC

by Zacks Equity Research

Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.